Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
General12 hours agoTributes flow after Australian Paralympic bronze medallist Nicholas Hum dies aged 32
-
Business20 hours agoWhat a rising Aussie dollar means for your ASX shares
-
General21 hours agoAussies skipping dental, medical care to afford rent
-
General7 hours agoReuven Morrison was killed in the Bondi Beach shooting one year after warning about antisemitism